Sign in Subscribe
Drugs

Chiron Expands Infectious Disease Franchises through $700 Million Acquisition of PathoGenesis

Strategic Insights

— 1 min read

Chiron Corporation, a leading biotechnology company, has entered into a definitive agreement to acquire PathoGenesis Corporation for approximately $700 million. The acquisition positions Chiron as a global player in the treatment and prevention of infectious diseases and cancer. The combined company will have a substantially expanded therapeutic focus in infectious disease, augmenting Chiron's established oncology franchise. Chiron will acquire PathoGenesis' five major commercial products, including TOBI, Proleukin, Betaseron, Menjugate, and Procleix, as well as more than 40 products on the market worldwide across Chiron's three business units.

Key Takeaways:

  • Chiron's acquisition of PathoGenesis expands its infectious disease franchises in biopharmaceuticals, vaccines, and blood testing, positioning the company as a global player in the treatment and prevention of infectious diseases and cancer.
  • The combined company will have a substantially expanded therapeutic focus in infectious disease, augmenting Chiron's established oncology franchise.
  • Chiron will acquire PathoGenesis' five major commercial products, including TOBI, Proleukin, Betaseron, Menjugate, and Procleix.
  • The acquisition adds more than 40 products on the market worldwide across Chiron's three business units.
  • Chiron will have an enhanced R&D capability in bacterial genomics and small molecule therapeutics, enabling the development of high-value, next-generation anti-infectives.
  • The acquisition will create a solid research and development engine for the treatment and prevention of serious infections, including hepatitis C, hepatitis B, and other bacterial pathogens.
  • Chiron has sequenced the meningococcal B genome and PathoGenesis has sequenced the P. aeruginosa genome, creating new opportunities for the development of next-generation therapeutic and prophylactic anti-infective products.
  • The acquisition is expected to close in the third or fourth quarter of 2000.

Statistics:

  • $700 million: The approximate value of the acquisition.
  • 5 major commercial products: TOBI, Proleukin, Betaseron, Menjugate, and Procleix, acquired by Chiron.
  • 40 products on the market worldwide: Across Chiron's three business units.
  • 350 people: Combined worldwide sales and marketing team of Chiron.
  • 15 additional European countries: To benefit from TOBI's European approval, marking a significant revenue growth opportunity.
  • 9,500 patients: Number of U.S. patients treated with TOBI.

Sources:

  • Chiron Corporation Press Release, August 14, 2000.
  • PathoGenesis Corporation Press Release, August 14, 2000.
  • Securities and Exchange Commission (SEC) filings, Chiron Corporation.

Read more